Author Archives: admin


Center for Regenerative Medicine – Mayo Clinic

Clinical Trials

Mayo Clinic offers a variety of clinical trials that are open for enrollment to participants who want to volunteer for research studies exploring regenerative medicine therapy.

Part of Mayo Clinic's commitment to its patients involves conducting medical research that can help people live longer, healthier lives. Clinical trials are research studies that involve volunteer participants. These studies help physician-scientists better understand, diagnose, treat, and prevent diseases and conditions.

Mayo Clinic's clinical trials related to regenerative medicine include studies on amytrophic lateral sclerosis (ALS), chronic obstructive pulmonary disease (COPD), congenital heart disease, diabetic kidney disease, Parkinson's disease, osteoarthritis and many more. Mayo Clinic also has thousands of other active clinical trials and research studies, and it coordinates national and international clinical trials with other medical institutions from around the world.

The Regenerative Medicine Consult Service, Mayo Clinic's front door to regenerative therapies and research, provides information and referrals to patients.

Phone: 844-276-2003 (toll-free)

Mayo Clinic has many active clinical trials related to transplantation, which is one component of regenerative medicine.

.

More:
Center for Regenerative Medicine - Mayo Clinic

Creative Medical Technology Holdings Announces Successful Application of ImmCelz Immunotherapy for Treatment of Stroke – PRNewswire

PHOENIX, Dec. 16, 2020 /PRNewswire/ --Creative Medical Technology Holdings Inc., (OTC CELZ) announced today positive preclinical data supporting the utilization of its ImmCelz cell based immunotherapy for treatment of stroke. In an animal model of ischemia stroke, the middle cerebral artery ligation model, administration of ImmCelz resulted in 34% reduction in infarct volume, whereas control bone marrow mesenchymal stem cells reduced infarct volume by 21%. Additionally, improvements in functional recovery where observed using the Rotarod test. At 28 days after induction of stroke the animals receiving ImmCelz had superior running time (92% of non-stroke controls) compared to animals which received bone marrow mesenchymal stem cells (73% of non-stroke control). Animals that received saline had a running time that was 50% of non-stroke controls.

"The regenerative potential of immune cells that have been programmed by stem cells is a fascinating and novel area of research." Said Dr. Amit Patel, coinventor of ImmCelz, and board member of the Company. "Conceptual advantages of using reprogrammed T cells include higher migratory ability due to smaller size, as well as ability to replicate and potentially form "regenerative memory cells."

"This data, which is covered by our previous filed patents, such as no. 15/987739, Generation of autologous immune modulatory cells for treatment of neurological conditions, demonstrate that immune modulation via this stem cell based method may be a novel and superior way of addressing the $30 billion dollar market for stroke therapeutics1." Said Dr. Thomas Ichim, coinventor of the patent and Chief Scientific Officer of the Company. "The fact that this technology, which has priority back to 2017, is demonstrating such stunning results, motivates us to consider filing an Investigational New Drug Application for use in stroke."

Creative Medical Technology Holdings possesses numerous issued patents in the area of cellular therapy including patent no. 10,842,815 covering use of T regulatory cells for spinal disc regeneration, patent no. 9,598,673 covering stem cell therapy for disc regeneration, patent no. 10,792,310 covering regeneration of ovaries using endothelial progenitor cells and mesenchymal stem cells, patent no. 8,372,797 covering use of stem cells for erectile dysfunction, and patent no. 7,569,385 licensed from the University of California covering a novel stem cell type.

"While stroke historically has been a major area of unmet medical need, the rise in stroke cases , as well as the fact that younger people are increasingly falling victim to stroke, strongly motivates us to accelerate our developmental programs and to continue to explore participation of Big Pharma in this space." Said Timothy Warbington, President and CEO of the Company. "We are eager to replicate the existing experiments start compiling the dossier needed to take ImmCelz into humans using the Investigational New Drug Application (IND) route through the FDA."

About Creative Medical Technology Holdings

Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company specializing in stem cell technology in the fields of urology, neurology and orthopedics and trades on the OTC under the ticker symbol CELZ. For further information about the company, please visitwww.creativemedicaltechnology.com.

Forward Looking Statements

OTC Markets has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming clinical trials and laboratory results, marketing efforts, funding, etc. Forward-looking statements address future events and conditions and, therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. See the periodic and other reports filed by Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission's website atwww.sec.gov.

Timothy Warbington, CEO [emailprotected] CreativeMedicalHealth.com

Creativemedicaltechnology.com http://www.StemSpine.com http://www.Caverstem.com http://www.Femcelz.com

1Stroke Management Market Size Forecasts 2026 | Statistics Report (gminsights.com)

SOURCE Creative Medical Technology Holdings, Inc.

Home

Follow this link:
Creative Medical Technology Holdings Announces Successful Application of ImmCelz Immunotherapy for Treatment of Stroke - PRNewswire

Glycostem and Ghent University sign license agreement on NK cell therapy technology – PRNewswire

OSS, Netherlands, Dec. 17, 2020 /PRNewswire/ --Glycostem Therapeutics B.V., a leading clinical-stage company focused on the development of therapeutic off-the-shelf Natural Killer (NK) cells, and Ghent University (UGent) have signed a license agreement for an innovative NK cell production technology. Ultimately, this agreement will bring significant benefit to targeted treatment of patients suffering from cancer. The agreement not only opens up new opportunities for development of NK-antibody combination therapies but also has significant positive impact on the production time of Glycostem's lead product oNKord and its second (CAR-NK) and third (TCR-NK) generation therapies viveNKTM.

"This license agreement offers new opportunities for more targeted treatment of cancer patients. By using UGent's technology we are able to increase the expression of CD16 receptors resulting in an increase of the NK-cell's activity and its antibody binding properties. When a patient's immunity is weak, administering NK-cells will boost the patient's immune system and increase the antibody's therapeutic effectiveness," explains Troels Jordansen, CEO at Glycostem.

Glycostem's NK-cell based therapies are manufactured in its in-house GMP licensed facility. "Ghent University's technology has the potential to almost halve the time needed for NK cell progenitor cells to differentiate into fully functional NK-cells. By incorporating this in our processes both our manufacturing time and cost-effectiveness will be affected very positively without negative effect on the potency of the NK cells. This is an important part of paving the way for further upscaling the production of our NK-cells," says Troels Jordansen.

"We are glad to see our research translated to a clinical setting as it is based on many years of fundamental research into NK cell biology," tells Prof. Georges Leclercq, head of the UGent research team and group leader in the Cancer Research Institute Ghent (CRIG). "We hope that with this collaboration, we can positively impact the lives of many patient's affected by difficult to treat cancers."

Dr. Dominic De Groote (UGent Business Development) further explains: "This partnership is the result of continuing efforts by Ghent University and Ghent University Hospital to become a leading academic and clinical center for cell-based therapies. This technology is part of our growing portfolio of oncology and Advanced Therapy Medicinal Products (ATMP) related assets that we are actively developing from the bench to the bedside through our translational platforms."

Taking cellular immunotherapy to the next level

Glycostem is focused on developing first, second and third generation cancer treatments based on NK-cells. This licensing deal will affect Glycostem's full portfolio. After a successful phase I study Glycostem initiated a first-of-its-kind pivotal trial in acute myeloid leukemia (AML) with in-house manufactured nonmodified NK cells (oNKord). Over the coming months, AML patients will receive this form of treatment as part of a phase I-IIa trial. A pivotal phase IIa trial for Multiple Myeloma (MM) patients is expected to start second half of 2021. This makes Glycostem one of the frontrunners in this promising field of cellular immunotherapy.

About Glycostem

Netherlands-based Glycostem Therapeutics BV, a clinical stage biotech company, develops allogeneic cellular immunotherapy to treat several types of cancer. By harnessing the power of stem cell-derived Natural Killer (NK) cells, Glycostem's products are a safe alternative to CAR-T-cells. Glycostem's lead product, oNKord, is manufactured from allogeneic raw material and is available off-the shelf. Thanks to its nine patent families, longstanding technical expertise and resources, as well as 'Orphan Drug Designation', Glycostem has secured a leadership position in the global NK-cell market.

oNKord is produced in a closed system (uNiKTM) in Glycostem's state-of-the-art and GMP (Good Manufacturing Practice) licensed production facility in the Netherlands, from which it can be distributed globally. The production technology includes ex vivo generation of high numbers of NK-cells with a high degree of purity for clinical applications. oNKord successfully passed phase I clinical trial (elderly and frail AML - Acute Myeloid Leukemia - patients), providing solid safety data and strong indication of clinical activity, including response on MRD (Minimal Residual Disease). Results indicate that oNKord may be safely infused in AML patients.

Glycostem is furthermore developing a range of CAR-NK and TCR-NK products in-house and in cooperation with global partners.

Glycostem Therapeutics BV http://www.glycostem.com

Foot note: "oNKord" is a registered trademark of Glycostem in the US and in Europe. Trademark registrations of "viveNK" and "uNiK" are pending.

About Ghent University

Ghent University (UGent) is a major Belgian university located in the heart of Europe. Our organization is dedicated to research and innovation with over 5,500 researchers active in a wide area of life, physical and social sciences. Strong partnerships with the Ghent University Hospital (1000+ beds), VIB, IMEC and global leaders in academia and pharma/biotech industry thrive life science innovation at our university and is part of the thriving Belgian biotech region. Our translational platforms such as CRIG (focus on cancer) and GATE (focus on advanced therapy medicinal products) facilitate to bring science to the patient.

Prof. Georges Leclercq has a longstanding and internationally recognized expertise in differentiation and function of NK cells. The recent focus of his research group is to reveal the role of several transcription factors in the differentiation of human hematopoietic stem cells into mature NK cells, and in the maintenance and function of these mature NK cells. The ultimate aim is to attribute to improved NK-based cancer immunotherapy.

Cancer Research Institute Ghent http://www.crig.ugent.be

SOURCE Glycostem

Visit link:
Glycostem and Ghent University sign license agreement on NK cell therapy technology - PRNewswire

Creative Medical Technology Stock Price Increased 80.77%: Why It Happened – Pulse 2.0

The stock price of Creative Medical Technology Holdings Inc (OTCMKTS: CELZ) a company that engages in stem cell research and developing applications to treat male sexual dysfunction and related issues increased by 80.77% yesterday as it went from $0.0026 to $0.0047 per share. One of the biggest triggers for the stock price increase is an announcement about the company announcing the successful application of ImmCelz immunotherapy for treatment of stroke.

In an animal model of ischemia stroke, the middle cerebral artery ligation model, administration of ImmCelz resulted in 34% reduction in infarct volume, whereas control bone marrow mesenchymal stem cells reduced infarct volume by 21%. And there were improvements in functional recovery were observed using the Rotarod test.

At 28 days after induction of stroke the animals receiving ImmCelz had superior running time (92% of non-stroke controls) compared to animals that received bone marrow mesenchymal stem cells (73% of non-stroke control). And animals that received saline had a running time that was 50% of non-stroke controls.

KEY QUOTES:

The regenerative potential of immune cells that have been programmed by stem cells is a fascinating and novel area of research. Conceptual advantages of using reprogrammed T cells include higher migratory ability due to smaller size, as well as ability to replicate and potentially formregenerative memory cells.

Dr.Amit Patel, coinventor of ImmCelz

This data, which is covered by our previous filed patents, such as no. 15/987739,Generation of autologous immune modulatory cells for treatment of neurological conditions, demonstrate that immune modulation via this stem cell based method may be a novel and superior way of addressing the$30 billion dollarmarket for stroke therapeutics. The fact that this technology, which has priority back to 2017, is demonstrating such stunning results, motivates us to consider filing an Investigational New Drug Application for use in stroke.

Dr.Thomas Ichim, coinventor of the patent and Chief Scientific Officer of Creative Medical Technology

While stroke historically has been a major area of unmet medical need, the rise in stroke cases , as well as the fact that younger people are increasingly falling victim to stroke, strongly motivates us to accelerate our developmental programs and to continue to explore participation of Big Pharma in this space. We are eager to replicate the existing experiments start compiling the dossier needed to take ImmCelz into humans using the Investigational New Drug Application (IND) route through the FDA.

Timothy Warbington, President and CEO of Creative Medical Technology

Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.

Read the rest here:
Creative Medical Technology Stock Price Increased 80.77%: Why It Happened - Pulse 2.0

Stem Cell Clinics: Effective or Pricey False Hope?

Second in a two-part series about stem cells. See the first entry here.

Aug. 13, 2019 -- Beverly Hills plastic surgeon Mark Berman says he can offer 12,000 reasons people should consider getting stem cell therapy at one of the clinics he co-founded across the country. Thats the number of patients he says his 100-plus affiliated clinics have treated for conditions like knee pain, erectile dysfunction, asthma, congestive heart failure, stroke, and Parkinsons disease. Sports figures have also publicized the therapies.

But a number of stem cell scientists say that these and other self-described stem cell clinics are misleading the public. The treatments, which often cost $5,000 to $20,000, have no proof of safety or effectiveness. In many cases, theres no logical scientific reason to think they might work, they say. And the procedures, which involve moving cells from one part of the body to another, arent really even stem cell therapies, according to scientists at Harvard University, New York University, the University of California, Davis, Arizona State University, the University of Minnesota, and others.

Stem cell therapies often involve taking cells from one area, like the abdomen, spinning them in a centrifuge to concentrate the cells, and then reinjecting them into another part of the body, like the knee.

Offering these procedures violates the standards of medical practice, says Insoo Hyun, PhD, a bioethicist at Harvard and Case Western Reserve University School of Medicine in Cleveland, OH.

Berman says the procedures that he offers are safe but adds that his clinics stopped providing stem cell shots into the eyeball after a woman treated for macular degeneration, a cause of age-related vision loss, had retinal detachments and went blind. Several other women treated elsewhere for macular degeneration were also blinded. Other reports blame stem cell procedures, mostly performed outside the United States, for tumors, infections, and brain inflammation.

Hyun says it may sound harmless to move your own cells around, but not all cells are the same. Your bodys stem cells -- theyre found, they work, and they live in a very particular system, he says. When you transfer them out of that system, theres no evidence theyre going to do anything except maybe cause harm because theyre in unfamiliar territory.

Hyun says theres no rational reason to try a stem cell therapy offered by one of these clinics, which are thought to number more than 700 across the country -- though he understands why desperate patients and families might be willing to take a risk for the promise of effective treatment. Some mainstream hospitals also offer stem cell and similar procedures, sometimes in the context of a research trial, sometimes not -- earning them the same criticisms as the clinics.

Hyun and others are quick to note that genuine treatments based on stem cells -- cells that can transform into different cell types -- have tremendous potential to eventually help patients with a wide range of ailments. But except for bone marrow transplants, which have been used for decades, and some research trials, which should be free to patients who volunteer, those treatments are not yet ready for patients, and certainly not for clinics in strip malls, Hyun says.

If they would actually cure a devastating disease, we would all know about it, he says.

The federal government has begun to crack down on these clinics, after largely ignoring them for years. The FDA has charged some clinics, including Bermans, with selling drugs without appropriate approvals and with unsafe manufacturing practices.

In late June, a federal judge in Florida sided with the FDA against two clinics there. In a statement at the time, the government said: Court decisions like this reaffirm the FDAs compliance and enforcement efforts in the ongoing fight to protect the public from individuals and clinics who mislead patients with unapproved and potentially harmful medical products.

Berman, who was not involved in the Florida case, has been sued by the FDA as co-founder of the California Stem Cell Treatment Center and the Cell Surgical Network. He argues that the federal government is overstepping its bounds by trying to regulate the procedures he offers.

He says hes just giving patients back their own cells, not making a drug, so the FDA has no jurisdiction. A procedure like skin grafting, for instance, where skin from one part of the body is moved to cover a wound elsewhere, isnt FDA-regulated.

All Im doing is giving you back your own stuff, Berman says. You own it.

But the FDA says that when a product is created from a persons own body, manipulated, and put back into the body, but for a different purpose, it could be considered a new product subject to FDA approval.

Stem cell products can create unique and serious risks depending on how theyre manipulated once theyre taken from the body and how they are used once theyre reinserted in the body, then-FDA Commissioner Scott Gottlieb, MD, and FDA Biologics Center Director Peter Marks, MD, said in April. When a product undergoes more than minimal manipulation, its characteristics may be changed in a way that are novel, and its risks and potential benefits unique.

Berman says that his procedures are very safe, and that the handful of injury lawsuits against stem cell clinics come from rare bad apples, or procedures that are no longer done.

Leigh Turner, PhD, a bioethicist at the University of Minnesota, says theres no way to know how patients have fared, because no one has been keeping track. Do we have a clear understanding of the number of people harmed by such procedures? I think the answer is: We probably dont, he says.

Stem cell clinics cloak their marketing in science, Turner and other scientists say. For example, they use proper scientific terms and fill their websites with explanations and links to scientific studies. Some clinics have patients sign waivers suggesting that their treatment is part of research. But most of these clinics have done little or no legitimate research, Turner says. Instead of publishing their findings in reputable, peer-reviewed journals where studies routinely change medical practice, these clinics publish in junk journals, if at all, he says.

Berman dismisses such scientific criticism. These are misinformed PhDs working in their labs who have their own special interests, he says.

The condition that Bermans clinics treat most often is knee pain, and stem cell therapies may someday become the first line of treatment for patients with mild knee arthritis, says Philipp Leucht, MD, an orthopedic surgeon with NYU Langone Health in New York.

Injecting cells from the fat or bone marrow into the knee is generally safe, says Leucht, also a member of the American Academy of Orthopaedic Surgeons Biologics and Regenerative Medicine Committee. The main thing that could go wrong is an infection where you get the shot.

Its a low-risk procedure, he says. Its expensive -- thats the highest risk, probably, that you have to pay for it.

But whether such shots are useful remains an open question. The science is still weak, Leucht says. There has never been a large, well-designed research trial, with patients getting the treatment compared to those receiving a placebo.

Some people with early-stage arthritis do seem to get pain relief with cell therapy, he says. (Leucht doesnt believe in calling the procedures stem cell therapies because so few actual stem cells are in the fat or bone marrow thats withdrawn and then injected into the knee. He prefers to call them cell therapies.) Its not clear why some patients report improvements and others dont, or how to target those most likely to benefit, he says.

Plus, Leucht says, any pain relief from cell therapy will likely be short-lived, because the relocated cells die off in a few days, and thus wont stop arthritis from getting worse over time.

This will be part of the future treatment for osteoarthritis, but we just have to understand it first, says Leucht, adding that weight loss, exercise, and treating inflammation with over-the-counter medications and a healthy diet are already proven ways to reduce knee pain. We cant trial it on patients first and then figure it out [scientifically].

The International Society for Stem Cell Research, a scientific group, publishes guidelines on its website to help patients decide what to consider when theyre thinking of getting treated at a stem cell clinic. Hyun co-wrote the most recent guidelines in 2016.

Before agreeing to treatments at stem cell clinics, you should ask questions about the procedure and the doctor performing it, say Emma Frow and David Brafman, both PhDs and assistant professors at Arizona State University. The pair helped co-author a study on the stem cell industry, published this month, that offered details about nearly 170 stem cell businesses in the Southwestern United States.

At those businesses, many specialists in orthopedics, sports medicine, and rehabilitation focused their stem cell treatments on conditions related to their specialty, according to the study, while specialists in cosmetic or alternative medicine were more likely to use cell therapies to treat a wide range of medical conditions. Next, the two say they want to examine the boards that are certifying some of these doctors as qualified.

But the lack of regulation and certification puts more pressure on patients to carefully consider the procedure and their doctors credentials, the pair says. Currently, Frow and Brafman say, the system is stacked against patients.

Theyre assuming all of the risk -- theyre assuming the personal risk, the physical risk, the financial risk, Frow says. We have a system at the moment really weighted toward benefiting the clinics, without a clear mechanism for benefiting patients and making sure they have recourse if things dont go well.

Turner agrees and thinks government regulators need to play more of a role. We put too much on shoulders of individual patients, and we ought to be expecting a lot more from regulatory bodies, he says.

Berman says he and others in the industry will continue to fight against tighter government regulations.

Were doing some amazing things, and were getting treated like were the scum of the earth, he says. Im sick of it, and we will beat the FDA in the court as long as the judge is willing to listen to the law.

But if the courts continue to uphold the FDAs right to regulate stem cell clinics, many of the procedures that Berman and his peers perform today wont be permitted.

That would transform the stem cell clinic industry, says Paul Knoepfler, PhD, a stem cell scientist at the University of California, Davis, School of Medicine, who tracks the field.

Some clinics might shut down, dropping out entirely, he says. For others, the temptation to continue doing some kind of stem cell stuff might be too great.

Knoepfler, a frequent critic of these clinics, thinks any reduction in their numbers would be good. I think fewer people will be put at risk.

Original post:
Stem Cell Clinics: Effective or Pricey False Hope?

FDA Warns About Stem Cell Therapies | FDA

Espaol

Researchers hope stem cells will one day be effective in the treatment of many medical conditions and diseases. But unproven stem cell treatments can be unsafeso get all of the facts if youre considering any treatment.

Stem cells have been called everything from cure-alls to miracle treatments. But dont believe the hype. Some unscrupulous providers offer stem cell products that are both unapproved and unproven. So beware of potentially dangerous proceduresand confirm whats really being offered before you consider any treatment.

The facts: Stem cell therapies may offer the potential to treat diseases or conditions for which few treatments exist. Sometimes called the bodys master cells, stem cells are the cells that develop into blood, brain, bones, and all of the bodys organs. They have the potential to repair, restore, replace, and regenerate cells, and could possibly be used to treat many medical conditions and diseases.

But the U.S. Food and Drug Administration is concerned that some patients seeking cures and remedies are vulnerable to stem cell treatments that are illegal and potentially harmful. And the FDA is increasing its oversight and enforcement to protect people from dishonest and unscrupulous stem cell clinics, while continuing to encourage innovation so that the medical industry can properly harness the potential of stem cell products.

To do your part to stay safe, make sure that any stem cell treatment you are considering is either:

And see the boxed section below for more advice.

The FDA has the authority to regulate stem cell products in the United States.

Today, doctors routinely use stem cells that come from bone marrow or blood in transplant procedures to treat patients with cancer and disorders of the blood and immune system.

With limited exceptions, investigational products must also go through a thorough FDA review process as investigators prepare to determine the safety and effectiveness of products in well-controlled human studies, called clinical trials. The FDA has reviewed many stem cell products for use in these studies.

As part of the FDAs review, investigators must show how each product will be manufactured so the FDA can make sure appropriate steps are being taken to help assure the products safety, purity, and strength (potency). The FDA also requires sufficient data from animal studies to help evaluate any potential risks associated with product use. (You can learn more about clinical trials on the FDAs website.)

That said, some clinics may inappropriately advertise stem cell clinical trials without submitting an IND. Some clinics also may falsely advertise that FDA review and approval of the stem cell therapy is unnecessary. But when clinical trials are not conducted under an IND, it means that the FDA has not reviewed the experimental therapy to help make sure it is reasonably safe. So be cautious about these treatments.

About FDA-approved Products Derived from Stem Cells

The only stem cell-based products that are FDA-approved for use in the United States consist of blood-forming stem cells (hematopoietic progenitor cells) derived from cord blood.

These products are approved for limited use in patients with disorders that affect the body system that is involved in the production of blood (called the hematopoietic system). These FDA-approved stem cell products are listed on the FDA website. Bone marrow also is used for these treatments but is generally not regulated by the FDA for this use.

All medical treatments have benefits and risks. But unproven stem cell therapies can be particularly unsafe.

For instance, attendees at a 2016 FDA public workshop discussed several cases of severe adverse events. One patient became blind due to an injection of stem cells into the eye. Another patient received a spinal cord injection that caused the growth of a spinal tumor.

Other potential safety concerns for unproven treatments include:

Note: Even if stem cells are your own cells, there are still safety risks such as those noted above. In addition, if cells are manipulated after removal, there is a risk of contamination of the cells.

When stem cell products are used in unapproved waysor when they are processed in ways that are more than minimally manipulated, which relates to the nature and degree of processingthe FDA may take (and has already taken) a variety of administrative and judicial actions, including criminal enforcement, depending on the violations involved.

In August 2017, the FDA announced increased enforcement of regulations and oversight of stem cell clinics. To learn more, see the statement from FDA Commissioner Scott Gottlieb, M.D., on the FDA website.

And in March 2017, to further clarify the benefits and risks of stem cell therapy, the FDA published a perspective article in the New England Journal of Medicine.

The FDA will continue to help with the development and licensing of new stem cell therapies where the scientific evidence supports the products safety and effectiveness.

Know that the FDA plays a role in stem cell treatment oversight. You may be told that because these are your cells, the FDA does not need to review or approve the treatment. That is not true.

Stem cell products have the potential to treat many medical conditions and diseases. But for almost all of these products, it is not yet known whether the product has any benefitor if the product is safe to use.

If you're considering treatment in the United States:

If you're considering treatment in another country:

Read the original post:
FDA Warns About Stem Cell Therapies | FDA

Global NK Cell Therapy and Stem Cell Therapy Market: Development, Current Analysis and Estimated Forecast to 2025 – The Courier

The research report on NK Cell Therapy and Stem Cell Therapy Market gives thorough insights regarding various key trends that shape the industry expansion with regards to regional perspective and competitive spectrum. Furthermore, the document mentions the challenges and potential restrains along with latent opportunities which may positively impact the market outlook in existing and untapped business spaces. Moreover, it presents the case studies, including the ones related to COVID-19 pandemic, to convey better understanding of the industry to all the interested parties.

The recent market trend of increasingly using NK Cell Therapy and Stem Cell Therapy for understanding the development of a disease extensively fuel the growth of this market in the coming years. Another trend that will aid the growth of the global NK Cell Therapy and Stem Cell Therapy market is the escalating demand for personalized medicine. Extensive investments are being made by various organizations, pharmaceutical companies, and governments for the research and development of drugs, and this is another trend that is benefiting the growth of the global NK Cell Therapy and Stem Cell Therapy market. This is because NK Cell Therapy and Stem Cell Therapy techniques enable researchers to compare NK Cell Therapy and Stem Cell Therapy changes between disease samples and normal samples. Public health can thus be analyzed as the changes in NK Cell Therapy and Stem Cell Therapy are influenced by internal biological system and environment directly.

Request a sample of this premium research: https://www.bigmarketresearch.com/request-sample/3930448?utm_source=Nilesh-MCC

The report covers extensive analysis of the key market players in the market, along with their business overview, expansion plans, and strategies. The key players studied in the report include: Osiris Therapeutics, Chiesi Pharmaceuticals, Molmed, Takeda Pharmaceutical, Medi-post, Chipscreen Biosciences, Affimed NV, JCR Pharmaceutical, Pharmicell, Innate Pharma SA, NuVasive, Anterogen, Altor BioScience Corporation.

NK Cell Therapy and Stem Cell Therapy Market Segmentation:

In market segmentation by types of NK Cell Therapy and Stem Cell Therapy, the report covers-

NK Cell Therapy Stem Cell Therapy

In market segmentation by applications of the NK Cell Therapy and Stem Cell Therapy, the report covers the following uses-

Hospital & clinics Regenerative medicine centers Diagnostic centers Research institutes Others

Regional Analysis for NK Cell Therapy and Stem Cell Therapy Market-:

1) North America- (United States, Canada)

2) Europe- (Germany, France, UK, Italy, Russia, Spain, Netherlands, Switzerland, Belgium)

3) Asia Pacific- (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Vietnam)

4) Middle East & Africa- (Turkey, Saudi Arabia, United Arab Emirates, South Africa, Israel, Egypt, Nigeria)

5) Latin America- (Brazil, Mexico, Argentina, Colombia, Chile, Peru)

The report provides insights on the following pointers :

Market Penetration: Comprehensive information on the product portfolios of the top players in the Supply Chain Analytics market.

Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and product launches in the market

Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market

Market Development: Comprehensive information about emerging markets. This report analyzes the market for various segments across geographies

Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the Supply Chain Analytics market

NOTE: Our analysis involves the study of the market taking into consideration the impact of the COVID-19 pandemic. Please get in touch with us to get your hands on an exhaustive coverage of the impact of the current situation on the market. Our expert team of analysts will provide as per report customized to your requirement.

Request a discount on standard prices of this premium research: https://www.bigmarketresearch.com/request-for-discount/3930448?utm_source=Nilesh-MCC

Table of Content

Chapter 1 NK Cell Therapy and Stem Cell Therapy Introduction and Market Overview

Chapter 2 Executive Summary

Chapter 3 Industry Chain Analysis

Chapter 4 Global NK Cell Therapy and Stem Cell Therapy Market, by Type

Chapter 5 NK Cell Therapy and Stem Cell Therapy Market, by Application

Chapter 6 Global NK Cell Therapy and Stem Cell Therapy Market Analysis by Regions

Chapter 7 North America NK Cell Therapy and Stem Cell Therapy Market Analysis by Countries

Chapter 8 Europe NK Cell Therapy and Stem Cell Therapy Market Analysis by Countries

Chapter 9 Asia Pacific NK Cell Therapy and Stem Cell Therapy Market Analysis by Countries

Chapter 10 Middle East and Africa NK Cell Therapy and Stem Cell Therapy Market Analysis by Countries

Chapter 11 South America NK Cell Therapy and Stem Cell Therapy Market Analysis by Countries

Chapter 12 Competitive Landscape

Chapter 13 Industry Outlook

Chapter 14 Global NK Cell Therapy and Stem Cell Therapy Market Forecast

Chapter 15 New Project Feasibility Analysis

Trending Market Research Reports :

Global Hirsutism-Treatment Market Research Report 2018:- https://www.mccourier.com/hirsutism-treatment-market-forecasts-allergan-abbvie-inc-bristol-myers-squibb-company-bayer-ag-sun-pharmaceutical-industries-ltd-pfizer-inc-more/

2020-2025 Global and Regional IoT Spending in Manufacturing Industry Production, Sales and Consumption Status and Prospects Professional Market Research Report:- https://www.mccourier.com/iot-spending-in-manufacturing-market-2020-covid-19-impact-analysis-business-outlook-growth-share-trends-and-forecasts-2025/

About Us:

Big Market Research has a range of research reports from various domains across the world. Our database of reports of various market categories and sub-categories would help to find the exact report you may be looking for.

Contact us:

Mr. Abhishek Paliwal

Big Market Research

5933 NE Win Sivers Drive, #205, Portland,

OR 97220 United States

Direct: +1-971-202-1575

Toll Free: +1-800-910-6452

E-mail: help@bigmarketresearch.com

Visit link:
Global NK Cell Therapy and Stem Cell Therapy Market: Development, Current Analysis and Estimated Forecast to 2025 - The Courier

ADMA Biologics Adopts Limited Duration Stockholder Rights Plan

RAMSEY, N.J. and BOCA RATON, Fla., Dec. 16, 2020 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that its Board of Directors has approved the adoption of a limited duration stockholder rights plan and declared a dividend distribution of one right for each outstanding share of common stock. The record date for such dividend distribution is December 30, 2020. The rights plan expires, without any further action being required to be taken by ADMA’s Board of Directors, on December 15, 2021.

Here is the original post:
ADMA Biologics Adopts Limited Duration Stockholder Rights Plan

SCYNEXIS Announces Launch of $50 Million Public Offering of Common Stock and Warrants

JERSEY CITY, N.J., Dec. 16, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq:SCYX) today announced that it has commenced an underwritten public offering of shares of its common stock and warrants to purchase shares of its common stock, including pre-funded warrants to purchase common stock in lieu of common stock for certain purchasers. All of the shares of common stock and warrants in the offering will be sold by SCYNEXIS. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.

Excerpt from:
SCYNEXIS Announces Launch of $50 Million Public Offering of Common Stock and Warrants

MacroGenics Announces FDA Approval of MARGENZA™ for Patients with Pretreated Metastatic HER2-Positive Breast Cancer

ROCKVILLE, MD, Dec. 16, 2020 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has approved MARGENZA, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. MARGENZA is the first product approved from MacroGenics’ promising pipeline. The approval was based on safety and efficacy results from the pivotal Phase 3 SOPHIA trial.

See original here:
MacroGenics Announces FDA Approval of MARGENZA™ for Patients with Pretreated Metastatic HER2-Positive Breast Cancer